Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | LATS1 | O95835 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 4/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17884782 | 1.00 | CHRNB2 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4RAD52 | |
| SCHEMBL17884677 | 0.84 | ADAMTS5 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4RAD52 | |
| SCHEMBL17884838 | 0.84 | CHRNB2 (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4LATS1 | |
| SCHEMBL30609634 | 0.84 | CHRNB2 (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4LATS1 | |
| SCHEMBL30609715 | 0.84 | ADAMTS5 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4RAD52 | |
| SCHEMBL27985661 | 0.82 | RAD52 (0.47) | RAD52LATS1GSK3BROCK2ROCK1 | |
| SCHEMBL27985663 | 0.82 | RAD52 (0.47) | RAD52LATS1GSK3BROCK2ROCK1 | |
| SCHEMBL17884776 | 0.81 | CHRNB2 (0.57) | CHRNB2CHRNB4CHRNA3CHRNA4RAD52 | |
| SCHEMBL21098421 | 0.81 | CHRNB2 (0.60) | CHRNB2CHRNB4CHRNA3CHRNA4LATS1 | |
| SCHEMBL21098418 | 0.81 | CHRNB2 (0.60) | CHRNB2CHRNB4CHRNA3CHRNA4LATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | CHRNB2 4643/4885CHRNB4 4801/4885CHRNA3 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.